Text Size:AAA

IGFBP3/IGFBP-3  Protein, Antibody, ELISA Kit, cDNA Clone

描述: Active  
表達宿主: Human Cells  
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
  • Slide 1
表達宿主: Human Cells  
5 µg 
20 µg 
100 µg 
Add to Cart
  • Slide 1

IGFBP3/IGFBP-3 相关研究领域

IGFBP3/IGFBP-3 相關信號通路

    IGFBP3/IGFBP-3 相關蛋白、抗體、cDNA基因、ELISA試劑盒

    IGFBP3/IGFBP-3 相關蛋白、抗體、cDNA基因、ELISA試劑盒

    Featured Reagent Products

    IGFBP3/IGFBP-3 概述&蛋白信息

    IGFBP3/IGFBP-3 相關資訊

    IGFBP3/IGFBP-3 研究背景

    基因概述: This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
    General information above from NCBI
    亞單位結構: Interacts with XLKD1 (By similarity). Binds IGF2 more than IGF1. Forms a ternary complex of about 140 to 150 kDa with IGF1 or IGF2 and a 85 kDa glycoprotein (ALS). Interacts with HN. Interacts with TMEM219. {ECO:0000250, ECO:0000269|PubMed:14561895, ECO:0000269|PubMed:1726837, ECO:0000269|PubMed:20353938}.
    結構域: The thyroglobulin type-1 domain mediates interaction with HN.
    亞細胞定位: Secreted {ECO:0000269|PubMed:20353938}.
    組織特異性: Expressed by most tissues. Present in plasma.
    發育階段: IGFBP3 levels are higher during extrauterine life and peak during puberty.
    誘導: Up-regulated in the presence of IGF1, insulin and other growth-stimulating factors such as growth hormone, EGF and phorbol esters.
    翻譯後修飾: Phosphorylation sites are present in the extracellular medium.
    相似的序列: Contains 1 IGFBP N-terminal domain. {ECO:0000255|PROSITE-ProRule:PRU00653}.; Contains 1 thyroglobulin type-1 domain. {ECO:0000255|PROSITE-ProRule:PRU00500}.
    General information above from UniProt

    The Insulin-like Growth Factor (IGF) signaling system plays a central role in cellular growth, differentiation and proliferation. IGFBP3 is the most abundant IGF binding protein in human serum and has been shown to be a growth inhibitory, apoptosis-inducing molecule, capable of acting via IGF-dependent and IGF-independent mechanisms. It appears to function both by cell cycle blockade and the induction of apoptosis. IGFBP3 can be transported to the nucleus by an importin beta mediated mechanism, where it has been shown to interact with the retinoid X receptor alpha and possibly other nuclear elements. IGFBP3 antiproliferative signalling appears to require an active transforming growth factor beta (TGF-beta) signalling pathway, and IGFBP3 stimulates phosphorylation of the TGF-beta signalling intermediates Smad2 and Smad3. IGFBP3 has IGF-independent roles in inhibiting cell proliferation in cancer cell lines. Nuclear transcription factor, retinoid X receptor (RXR)-alpha, and IGFBP3 functionally interact to reduce prostate tumor growth and prostate-specific antigen in vivo. Several clinical studies have proposed that individuals with IGFBP3 levels in the upper range of normal may have a decreased risk for certain common cancers. This includes evidence of a protective effect against breast cancer, prostate cancer, colorectal cancer, and lung cancer. Moreover, IGFBP3 inhibits insulin-stimulated glucose uptake into adipocytes independent of IGF.

    IGFBP3/IGFBP-3 別稱

    IBP3,BP-53, [homo-sapiens]
    BP-53,IBP3,IGFBP3,tcag7.703, [human]
    AI649005,Igfbp3,IGFBP-3,IGgfbp3,RP23-20C9.1, [mouse]
    IGFBP-3,IGgfbp3,AI649005, [mus-musculus]

    IGFBP3/IGFBP-3 相關文獻

  • Baxter RC. (2001) Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol. 54(3): 145-8.
  • Butt AJ, et al. (2001) IGFBP-3 and apoptosis--a license to kill? Apoptosis. 6(3): 199-205.
  • Ali O, et al. (2003) Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res. 35(11-12): 726-33.
  • Yamada PM, et al. (2009) Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 296(5): C954-76.
  • 請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”